1Yano T, Sugio K, Yamazaki K, et al. Postoperative adjuvant adoptive immunotherapy with lymph node - LAK cells and IL - 2 for pathologic stage I non- small cell lung cancer[J]. Lung Cancer, 1999,26 (3): 143-148.
2Zhukova OS, Gerasimova GK, Shubina I, et al. Combined effect of cisplatin and lymphokine - activated killer cells on A549 cells of non -small cell lung cancer[J]. Bull Exp Biol Meal, 2007, 144(2) :231 - 234.
3Petersen RP, Campa MJ, Sperlazza J, et al. Tumor infiltrating Foxp3^+ regulatory T - cells arc associated with recurrence in patholog- ic stage I NSCLC patients[ J]. Cancer, 2006, 107 (12) : 2866 - 2872.
4Li R, Wang C, Liu L, et al. Autologous cytokine - induced kiUer cell immunotherapy in lung cancer: a phase II clinical study[ J]. Cancer Immunol Immunother, 2012, 61 ( 11 ) : 2125 - 2133.
5Kimura H, Iizasa T, Ishikawa A, et al. Prospective phase II study of post - surgical adjuvant chemo - immunotherapy using autologous den- dritic cells and activated killer ceils from tissue culture of tumor - draining lymph nodes in primary lung cancer patients[J]. Anticancer Res, 2008, 28(2B) : 1229- 1238.
6Yang L, Ren B, Li H, et al. Enhanced antitumor effects of DC - ac- tivated CIKs to chemotherapy treatment in a single cohort of advanced non - small - cell lung cancer patients [ J ]. Cancer Immunol Immu- nother, 2013, 62(1): 65-73.
7Zhong R, Han B, Zhong H. A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine - induced killer cells, and chemotherapy in advanced non - small cell lung cancer pa- tients[J]. TumourBiol, 2014, 35(2): 987-994.
8Fisher JP, Heuijerjans J, Yah M, et al. gammadeha T ceils for canc- er immunotherapy: a systematic review of clinical trials[ J]. Oncoim- munology, 2014, 3(1) : e27572.
9Nakajima J, Murakawa T, Fukami T, et al. A phase I study of a- doptive immunotherapy for recurrent non - small - cell lung canter pa- tients with autologous gammadeha T cells [ J ]. Eur J Cardiothorac Surg, 2010, 37(5): 1191 -1197.
10Pirker R, Pereira JR, yon Pawel J, et al. EGFR expression as a pre- dictor of survival for first - line chemotherapy plus cetuximab in pa- tients with advanced non - small - cell lung cancer: analysis of data from the phase 3 FLEX study [ J ]. Lancet Oncol, 2012,13 ( 1 ) : 33 - 42.
